


| | | | |
|--|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 09531-016002 | Application No. 10/031,005 |
| | Applicant Gary L. Nelsestuen | | |
| | Filing Date October 29, 2001 | Group Art Unit 1646 1653 1656 | |

| U.S. Patent Documents | | | | | | | |
|-----------------------|-----------|---------------|------------|-------------------|-------|-------------|----------------------------|
| Examiner Initial | Desig. ID | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date If Appropriate |
| HS | AA | 5,093,317 | 03/03/92 | Lewis et al. | 514 | 12 | |
| HS | AB | 5,258,288 | 11/02/93 | Wydro et al. | 435 | 69.6 | |
| HS | AC | 5,288,629 | 02/22/94 | Berkner | 435 | RECEIVED | |
| HS | AD | 5,504,064 | 04/02/96 | Morrissey et al. | 514 | JUN 12 2002 | |
| HS | AE | 5,516,640 | 05/14/96 | Watanabe et al. | 435 | 7.4 | |
| HS | AF | 5,580,560 | 12/03/96 | Nicolaisen et al. | 424 | 94.64 | TECH CENTER 600/2900 |
| HS | AG | 5,788,965 | 08/04/98 | Berkner et al. | 424 | 94.64 | |
| HS | AH | 5,817,788 | 10/06/98 | Berkner et al. | 536 | 23.2 | |
| HS | AI | 5,824,639 | 10/20/98 | Berkner | 514 | 12 | |
| HS | AJ | 5,833,982 | 11/20/98 | Berkner et al. | 424 | 94.64 | |
| HS | AK | 5,837,843 | 11/17/98 | Smimov et al. | 536 | 23.5 | |
| HS | AL | 5,847,085 | 12/08/98 | Esmon et al. | 530 | 381 | |
| HS | AM | 5,861,374 | 01/19/99 | Berkner et al. | 514 | 8 | |
| HS | AN | 6,017,882 | 01/25/00 | Nelsestuen | 514 | 12 | |


| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | | |
|---|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|----|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
| | | | | | | | Yes | No |
| HS | AO | 0 296 413 A2 | 12/28/88 | EPO | — | — | | |
| HS | AP | 0 354 504 A2 | 02/14/90 | EPO | — | — | | |
| HS | AQ | WO 99/20767 | 04/29/99 | PCT | — | — | | |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|--|-----------|--|
| Examiner Initial | Desig. ID | Document |
| HS | AR | Arnlijots et al., "Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa," <u>J. Vasc. Surg.</u> , 1997, 25(2):341-346 |
| HS | AS | Bauer, "Treatment of factor VII deficiency with recombinant factor VIIa," <u>Haemostasis</u> , 1996, 26(Suppl. 1):155-158 |
| HS | AT | Broze et al., "Monoclonal anti-human factor VII antibodies. Detection in plasma of a second protein antigenically and genetically related to factor VII," <u>J. Clin. Invest.</u> , 1985, 76:937-946 |
| HS | AU | Choudhri et al., "Targeted Inhibition of Intrinsic Coagulation Limits Cerebral Injury in Stroke without Increasing Intracerebral Hemorrhage," <u>J. Exp. Med.</u> , 1999, 190:91-99 |
| Examiner Signature  | | Date Considered 9-28-05 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | |

| | | | |
|--|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 09531-016002 | Application No. 10/031,665 |
| | Applicant Gary L. Nelsestuen | | |
| | Filing Date October 29, 2001 | Received at 1646 1656 | |

Other Documents (include Author, Title, Date, and Place of Publication)

| Examiner Initial | Desig. ID | Document |
|------------------|-----------|---|
| AS | AV | Christiansen et al., "Hydrophobic Amino Acid Residues of Human Anticoagulation Protein C that Contribute to its Functional Binding to Phospholipid Vesicles," <u>Biochemistry</u> , 1995, 34:10376-10382 |
| AS | AW | Dackiw et al., "Prevention of endotoxin-induced mortality by antitissue factor immunization," <u>Arch. Surg.</u> , 1996, 131:1273-1278 |
| AS | AX | Dahlback, "Inherited Thrombophilia: Resistance to Activated Protein C as a Pathogenic Factor of Venous Thromboembolism," <u>Blood</u> , 1995, 85:607-614 |
| AS | AY | Esmon et al., "Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C," <u>J. Biol. Chem.</u> , 1982, 257:859-864 |
| AS | AZ | Evans, Jr. and Nelsestuen, "Importance of <i>cis</i> -Proline 22 in the Membrane-Binding Conformation of Bovine Prothrombin," <u>Biochemistry</u> , 1996, 35:8210-8215 |
| AS | AAA | Evans and Nelsestuen, "Importance of <i>Cis</i> -Proline 22 and the Aromatic Stack (Residues 41-45) for Prothrombin-Membrane Binding," <u>Protein Sci.</u> , 1996, 5(Suppl. 1):163, Abstract #606-S |
| AS | ABB | Felgner et al., "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure," <u>Proc. Natl. Acad. Sci. USA</u> , 1987, 84:7413-7417 |
| AS | ACC | Fiore et al., "The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa," <u>J. Biol. Chem.</u> , 1994, 269:143-149 |
| AS | ADD | Freedman et al., "Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX," <u>J. Biol. Chem.</u> , 1996, 271(27):16227-16236 |
| AS | AEE | Furie and Furie, "The molecular basis of blood coagulation," <u>Cell</u> , 1988, 53:505-518 |
| AS | AFF | Han et al., "Isolation of a protein Z-dependent plasma protease inhibitor," <u>Proc. Natl. Acad. Sci. USA</u> , 1998, 95:9250-9255 |
| AS | AGG | He et al., "Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-S-defining modules important for the species specificity of the activated protein C cofactor activity," <u>Eur. J. Biochem.</u> , 1995, 227:433-440 |
| AS | AHH | Hedner et al., "Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients with Inherited and Acquired Bleeding Disorders," <u>Transfus. Med. Rev.</u> , 1993, 7:78-83 |
| AS | AII | Hope et al., "Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure. Characterization of Size Distribution, Trapped Volume and Ability to Maintain a Membrane Potential," <u>Biochem. Biophys. Acta</u> , 1985, 812:55-65 |
| AS | AJJ | Hoskins et al., "Cloning and characterization of human liver cDNA encoding a protein S precursor," <u>Proc. Natl. Acad. Sci. USA</u> , 1987, 84:349-353 |
| AS | AKK | Huang, <u>Biochemistry</u> , 1969, 8:344-352 |
| AS | ALL | Humphries et al., "Chemical methods of protein synthesis and modification," <u>Curr. Opin. Biotechnol.</u> , 1991, 2(4):539-543 |
| AS | AMM | Lu and Nelsestuen, "Dynamic Features of Prothrombin Interaction with Phospholipid Vesicles of Different Size and Composition: Implications for Protein - Membrane Contact," <u>Biochemistry</u> , 1996, 35:8193-8200 |
| AS | ANN | Lu and Nelsestuen, "The prothrombinase reaction: "mechanism switching" between Michaelis-Menten and non-Michaelis-Menten behaviors," <u>Biochemistry</u> , 1996, 35:8201-8209 |
| AS | AOO | Matsubara et al., "A receptor tyrosine kinase, Sky, and its ligand Gas 6 are expressed in gonads and support primordial germ cell growth or survival in culture," <u>Dev. Biol.</u> , 1996, 180:499-510 |

| | |
|--|----------------------------|
| Examiner Signature  | Date Considered 9-28-05 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 09531-016002 | Application No. 10/031,005 |
| | | Applicant Gary L. Nelsestuen | |
| | | Filing Date October 29, 2001 | Group 1646 1656 |


RECEIVED

JUN 12 2002

TECH CENTER 1600/2900

Other Documents (include Author, Title, Date, and Place of Publication)


| Examiner Initial | Desig. ID | Document |
|------------------|-----------|---|
| HS | APP | Mayer et al., "Prothrombin Association with Phospholipid Monolayers," <u>Biochemistry</u> , 1983, 22(2):316-321 |
| HS | AQQ | McDonald et al., "Comparison of Naturally Occurring Vitamin K-dependent Proteins: Correlation of Amino Acid Sequences and Membrane Binding Properties Suggests a Membrane Contact Site," <u>Biochemistry</u> , 1997, 36:5120-5127 |
| HS | ARR | McDonald et al., "Ionic Properties of Membrane Association by Vitamin K-Dependent Proteins: The Case for Univalency," <u>Biochemistry</u> , 1997, 36(50):15589-15598 |
| HS | ASS | Morrissey et al., "Quantitation of Activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selectively Deficient in Promoting Factor VII Activation," <u>Blood</u> , 1993, 81(3):734-744 |
| HS | ATT | Muir et al., "The chemical synthesis of proteins," <u>Curr. Opin. Biotechnol.</u> , 1993, 4(4):420-427 |
| HS | AUU | Nakagaki et al., "Initiation of the Extrinsic Pathway of Blood Coagulation: Evidence for the Tissue Factor Dependent Autoactivation of Human Coagulation Factor VII," <u>Biochemistry</u> , 1991, 30:10819-10824 |
| HS | AVV | Nelsestuen and Suttie, "Properties of Asialo and Aglycoprothrombin," <u>Biochem. Biophys. Res. Commun.</u> , 1971, 45:198-203 |
| HS | AWW | Nelsestuen et al., "Equilibria Involved in Prothrombin- and Blood Clotting Factor X-Membrane Binding," <u>Biochemistry</u> , 1977, 16(19):4164-4171 |
| HS | AXX | Nicolaes et al., "A prothrombinase-based assay for detection of resistance to activated protein C," <u>Thromb. Haemost.</u> , 1996, 76:404-410 |
| HS | AYY | Nicolaisen et al., "Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use," <u>Thromb. Haemost.</u> , 1996, 76:200-204 |
| HS | AZZ | Perera et al., "Trans-cis Isomerization of Proline 22 in Bovine Prothrombin Fragment 1: A Surprising Result of Structural Characterization," <u>Biochemistry</u> , 1998, 37:10920-10927 |
| HS | AAAA | Persson and Nielsen, "Site-directed mutagenesis but not gamma-carboxylation of Glu-35 in factor VIIa affects the association with tissue factor," <u>FEBS Letters</u> , 1996, 385(3):241-243 |
| HS | ABBB | Petersen et al., "Quenching of the amidolytic activity of one-chain tissue-type plasminogen activator by mutation of lysine-416," <u>Biochemistry</u> , 1990, 29:3451-3457 |
| HS | ACCC | Ratcliffe et al., "The Importance of Specific γ -Carboxyglutamic Acid Residues in Prothrombin," <u>J. Biol. Chem.</u> , 1993, 268(32):24339-24345 |
| HS | ADDD | Resnick and Nelsestuen, "Prothrombin-Membrane Interaction. Effects of Ionic Strength, pH, and Temperature," <u>Biochemistry</u> , 1980, 19(13):3028-3033 |
| HS | AEEE | Rezaie and Esmon, "The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives," <u>J. Biol. Chem.</u> , 1992, 267:26104-26109 |
| HS | AFFF | Schmidel et al., "Organization of the Human Protein S Genes," <u>J. Biol. Chem.</u> , 1990, 265(34):7845-7852 |
| HS | AGGG | Schulman et al., "Feasibility of using recombinant factor VIIa in continuous infusion," <u>Thromb. Haemost.</u> , 1996, 75(3):432-436 |
| HS | AHHH | Schwalbe et al., "Protein Structural Requirements and Properties of Membrane Binding by γ -Carboxyglutamic Acid-containing Plasma Proteins and Peptides," <u>J. Biol. Chem.</u> , 1989, 264:20288-20296 |
| HS | AIII | Seshadri et al., "Differences in the Metal Ion Structure between Sr- and Ca-Prothrombin Fragment 1," <u>Biochemistry</u> , 1994, 33:1087-1092 |


| | |
|--|----------------------------|
| Examiner Signature  | Date Considered 9-28-05 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 09531-016002 | Application No. 10/031,005 |
| | | Applicant Gary L. Nelsestuen | |
| | Filing Date October 29, 2001 | Group 1646 1650 | |

RECEIVED JUN 12 2002 TECH CENTER 1600/2900

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|--|
| Examiner Initial | Desig. ID | Document |
| JS | AJJJ | Shah et al., "Manipulation of the membrane binding site of vitamin K-dependent proteins: Enhanced biological function of human factor VII," <u>Proc. Natl. Acad. Sci. USA</u> , 1998, 95(8):4229-4234 |
| JS | AKKK | Shen et al., "Enhancing the Activity of Protein C by Mutagenesis to Improve the Membrane-Binding Site: Studies Related to Proline 10," <u>Biochemistry</u> , 1997, 36(51):16025-16031 |
| JS | ALLL | Shen et al., "Enhancement of Human Protein C Function by Site-directed Mutagenesis of the γ -Carboxyglutamic Acid Domain," <u>J. Biol. Chem.</u> , 1998, 273(47):31086-31091 |
| JS | AMMM | Smirnov et al., "A Chimeric Protein C Containing the Prothrombin Gla Domain Exhibits Increased Anticoagulant Activity and Altered Phospholipid Specificity," <u>J. Biol. Chem.</u> , 1998, 273(15):9031-9040 |
| JS | ANNN | Sorensen et al., "Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor," <u>J. Biol. Chem.</u> , 1997, 272(18):11863-11868 |
| JS | AOOO | Thariath et al., "Highly conserved residue arginine-15 is required for the Ca^{2+} -dependent properties of the γ -carboxyglutamic acid domain of human anticoagulation Protein C and activated Protein C," <u>Biochem. J.</u> , 1997, 322:309-315 |
| JS | APPP | Thomsen et al., "Pharmacokinetics of recombinant factor VIIa in the rat - a comparison of bio-, immuno- and isotope assays," <u>Thromb. Haemost.</u> , 1993, 70(3):458-464 |
| JS | AQQQ | Vallette et al., "Construction of mutant and chimeric genes using the polymerase chain reaction," <u>Nucleic Acids Res.</u> , 1989, 17(2):723-733 |
| JS | ARRR | Vrana et al., "Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family," <u>Cancer Res.</u> , 56:5063-5070 |
| JS | ASSS | Weber et al., "Modifications of Bovine Prothrombin Fragment 1 in the Presence and Absence of Ca(II) Ions," <u>J. Biol. Chem.</u> , 1992, 267(7):4564-4569 |
| JS | ATTT | Wei et al., "Kinetic and Mechanistic Analysis of Prothrombin-Membrane Binding by Stopped-Flow Light Scattering," <u>Biochemistry</u> , 1982, 21:1949-1959 |
| JS | AUUU | Welsch et al., "Chemical Modification of Prothrombin Fragment 1: Documentation of Sequential, Two-Stage Loss of Protein Function," <u>Biochemistry</u> , 1988, 27:4933-4938 |
| JS | AVVV | Welsch and Nelsestuen, "Amino-terminal alanine functions in a calcium-specific process essential for membrane binding by prothrombin fragment 1," <u>Biochemistry</u> , 1988, 27:4939-4945 |
| JS | AWWW | Yan et al., "Characterization and Novel Purification of Recombinant Human Protein C from Three Mammalian Cell Lines," <u>Bio/Technology</u> , 1990, 8:655-661 |
| JS | AXXX | Zhang et al., "Role of Individual γ -Carboxyglutamic Acid Residues of Activated Human Protein C in Defining its In Vitro Anticoagulant Activity," <u>Blood</u> , 1992, 80(4):942-952 |
| JS | AYYY | Zhang et al., "The Contributions of Individual γ -Carboxyglutamic Acid Residues in the Calcium-dependent Binding of Recombinant Human Protein C to Acidic Phospholipid Vesicles," <u>J. Biol. Chem.</u> , 1993, 268(16):12040-12045 |
| JS | AZZZ | Zwaal et al., "Lipid-protein interactions in blood coagulation," <u>Biochimica et Biophysica Acta</u> , 1998, 1376:433-453 |

| | |
|---|----------------------------|
| Examiner Signature  | Date Considered 9-28-05 |
| EXAMINER: Initials of person considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |


Sheet 1 of 1

| | | | |
|--|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 09531-016002 | Application No. 10/031,005 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Gary L. Nelsestuen | |
| | | Filing Date October 29, 2001 | Group Art Unit 1653 1656 |

| U.S. Patent Documents | | | | | | | |
|-----------------------|-----------|-----------------|------------------|----------|-------|----------|----------------------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | | |
|---|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|----|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
| | | | | | | | Yes | No |
| AS | AL | WO 88/10295 | 12/29/88 | PCT | — | — | | |
| | AM | | | | | | | |
| | AN | | | | | | | |
| | AO | | | | | | | |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|----------|
| Examiner Initial | Desig. ID | Document |
| | AP | |
| | AQ | |
| | AR | |
| | AS | |

| | |
|--|----------------------------|
| Examiner Signature  | Date Considered 9-28-05 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

Substitute Disclosure Form (PTO-1449)